{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:59:53Z","timestamp":1792511993474,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-025-01085-z","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T02:37:12Z","timestamp":1771209432000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Successful living kidney transplantation in a T-cell flow cytometry crossmatch-positive patient with atypical hemolytic uremic syndrome treated with an anti-C5 antibody: a case report"],"prefix":"10.1007","volume":"15","author":[{"given":"Masayoshi","family":"Okumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kurose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Segawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Komaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Ukimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8589-5218","authenticated-orcid":false,"given":"Keiichi","family":"Tamagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"1085_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrneph.2010.155","volume":"7","author":"J Zuber","year":"2011","unstructured":"Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Fremeaux-Bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol. 2011;7:23\u201335.","journal-title":"Nat Rev Nephrol"},{"key":"1085_CR2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"TH Goodship","year":"2017","unstructured":"Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2017;91:539\u201351.","journal-title":"Kidney Int"},{"key":"1085_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.trre.2017.10.001","volume":"32","author":"N Garg","year":"2018","unstructured":"Garg N, Rennke HG, Pavlakis M, Zandi-Nejad K. De novo thrombotic microangiopathy after kidney transplantation. Transpl Rev (Orlando). 2018;32:58\u201368.","journal-title":"Transpl Rev (Orlando)"},{"key":"1085_CR4","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.4049\/jimmunol.140.4.1304","volume":"140","author":"C Nahmias","year":"1988","unstructured":"Nahmias C, Strosberg AD, Emorine LJ. The immune response toward beta-adrenergic ligands and their receptors. VIII. Extensive diversity of VH and VL genes encoding anti-alprenolol antibodies. J Immunol. 1988;140:1304\u201311.","journal-title":"J Immunol"},{"key":"1085_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/tri.13269","author":"D Okada","year":"2018","unstructured":"Okada D, Okumi M, Kakuta Y, Unagami K, Iizuka J, Takagi T, et al. Outcome of the risk-stratified desensitization protocol in donor-specific antibody-positive living kidney transplant recipients: a retrospective study. Transpl Int. 2018. https:\/\/doi.org\/10.1111\/tri.13269.","journal-title":"Transpl Int"},{"key":"1085_CR6","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844\u201359.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1085_CR7","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8:554\u201362.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1085_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","volume":"31","author":"C Loirat","year":"2016","unstructured":"Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15\u201339.","journal-title":"Pediatr Nephrol"},{"key":"1085_CR9","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1055\/s-0034-1376153","volume":"40","author":"M Riedl","year":"2014","unstructured":"Riedl M, Fakhouri F, Le Quintrec M, Noone DG, Jungraithmayr TC, Fremeaux-Bacchi V, et al. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost. 2014;40:444\u201364.","journal-title":"Semin Thromb Hemost"},{"key":"1085_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.4049\/jimmunol.1600280","volume":"197","author":"JA Schatz-Jakobsen","year":"2016","unstructured":"Schatz-Jakobsen JA, Zhang Y, Johnson K, Neill A, Sheridan D, Andersen GR. Structural basis for eculizumab-mediated inhibition of the complement terminal pathway. J Immunol. 2016;197:337\u201344.","journal-title":"J Immunol"},{"key":"1085_CR11","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1111\/ajt.15364","volume":"19","author":"WH Marks","year":"2019","unstructured":"Marks WH, Mamode N, Montgomery RA, Stegall MD, Ratner LE, Cornell LD, et al. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial. Am J Transpl. 2019;19:2876\u201388.","journal-title":"Am J Transpl"},{"key":"1085_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1465851","volume":"15","author":"GY Heo","year":"2024","unstructured":"Heo GY, Jung M, Piao H, Kim HJ, Kim HW, Lee J, et al. Successful eculizumab treatment as an adjunctive therapy to desensitization in ABO-incompatible living donor kidney transplantation and its molecular phenotypes. Front Immunol. 2024;15:1465851.","journal-title":"Front Immunol"},{"key":"1085_CR13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.blre.2014.09.001","volume":"28","author":"A Verbiest","year":"2014","unstructured":"Verbiest A, Pirenne J, Dierickx D. De novo thrombotic microangiopathy after non-renal solid organ transplantation. Blood Rev. 2014;28:269\u201379.","journal-title":"Blood Rev"},{"key":"1085_CR14","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/tri.12706","volume":"29","author":"F Eskandary","year":"2016","unstructured":"Eskandary F, Wahrmann M, Muhlbacher J, Bohmig GA. Complement inhibition as potential new therapy for antibody-mediated rejection. Transpl Int. 2016;29:392\u2013402.","journal-title":"Transpl Int"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-01085-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-025-01085-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-01085-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:05:57Z","timestamp":1771430757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-025-01085-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":14,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1085"],"URL":"https:\/\/doi.org\/10.1007\/s13730-025-01085-z","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consultancies: Masayoshi Okumi (Alexion Pharmaceuticals Inc.), Honoraria: Masayoshi Okumi (Astellas Pharm Inc. and Alexion Pharmaceuticals Inc.). The remaining authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the patient in this report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"56"}}